Developer docs
API playgroundTry for free, no card

Search company profiles

Redesign Science

Full company profile

uuid0002b9a

Namestring
Redesign Science
Legal namestring
Redesign Science
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Redesign Science is a pre-revenue, New York-based computational biotechnology company that combines physics-based molecular dynamics with generative AI through its NUVO™ platform to discover first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™) for oncology, autoimmune, and rare disease indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational drug discovery, molecular dynamics simulation, generative AI drug design, small molecule therapeutics, protein interaction modulators
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Computational Drug Discovery Platform
Social media profiles2 records
Revenue model1 record
1Therapeutic Pipeline Development
TypeLicensing Royalties
Description

Pre-revenue biotech company developing small molecule therapeutics. Revenue will be generated through partnering deals with pharmaceutical companies, licensing agreements, or eventual product sales upon regulatory approval.

prnewswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Redesign Science develops the NUVO™ platform, which combines physics-based atomic-level molecular dynamics with generative AI to identify druggable binding sites on proteins and design novel small molecules. The platform powers the company's internal pipeline of first-in-class Targeted Protein Interaction Modulators (TPIM™) across oncology, autoimmune, and rare disease indications, intended to be monetized through pharmaceutical licensing and partnership deals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Redesign Science operates as a unified platform-plus-products architecture centered on its NUVO™ technology platform, which integrates physics simulation with generative AI. The NUVO platform consists of three core sub-products: NUVO Matisse (enhanced sampling physics for structural data), NUVO Picasso (generative AI for novel compounds), and NUVO Cézanne (machine learning for predictive scoring). This platform serves the company's internal therapeutics pipeline of first-in-class small molecule TPIM™ (Targeted Protein Interaction Modulators) across oncology, autoimmune, and rare disease indications.

Product and service2 records
1NUVO™ Platform
CategoryComputational Drug Discovery Platform
Description

Integrated physics, chemistry, and synthetic data platform that combines physics simulation with generative AI to enable dynamic structure-based drug discovery and serves the company's internal small molecule therapeutics pipeline.

2TPIM™ (Targeted Protein Interaction Modulators)
CategorySmall Molecule Therapeutics
Description

First-in-class small molecule therapeutic modality developed by Redesign Science to modulate targeted protein-protein interactions and provide unprecedented control over cellular biology, pursued across oncology, autoimmune, and rare disease indications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Machine learning-driven drug discovery company combining high-throughput biology with predictive models for small molecule therapeutics. Comparable platform-plus-pipeline business model with pharma collaborations.

TypeDirect peer
Description

AI-focused small molecule drug discovery company using structure-based deep learning to screen billions of compounds. Comparable as a tech-first platform pursuing pharma partnerships and internal programs.

TypeDirect peer
Description

Public computational drug discovery company combining physics-based molecular simulation with ML for small molecule discovery. Most directly comparable to Redesign Science given the shared physics-first platform philosophy and pharma-licensing business model.

TypeDirect peer
Description

Clinical-stage precision medicine company using protein motion visualization and computational chemistry to discover small molecule drugs. Closely aligned with Redesign Science's NUVO Matisse approach to leveraging dynamic protein structures for drug discovery.

TypeDirect peer
Description

AI and physics-based drug discovery company combining quantum physics, molecular dynamics, and AI for small molecule and crystal design. Directly comparable technology stack and CRO/partnership model.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning for small molecule therapeutics. Comparable as a publicly-listed AI/biotech platform advancing an internal pipeline plus pharma partnerships.

7Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed AI drug discovery company leveraging DeepMind's protein structure prediction (AlphaFold) for drug discovery. Broad incumbent with significantly more capital and the ability to leverage Alphabet's AI infrastructure.

TypeEmerging player
Description

AI-driven drug discovery company combining physics-based modeling with generative AI for small molecule design. Emerging player with significant overlap to Redesign Science's integrated physics+AI platform approach.

TypeEmerging player
Description

Generative biology company using machine learning to design novel protein therapeutics. Partially overlapping as a tech-first platform company using AI for therapeutic design, though focused on biologics rather than small molecules.

TypeEmerging player
Description

AI-driven degrader and small molecule discovery company using graph neural networks and physics-based approaches. Comparable as an emerging computational platform pursuing difficult-to-drug targets through AI/ML approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Redesign Science

Computational Drug Discovery Platformredesignscience.com

Redesign Science is a pre-revenue, New York-based computational biotechnology company that combines physics-based molecular dynamics with generative AI through its NUVO™ platform to discover first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™) for oncology, autoimmune, and rare disease indications.

Redesign Science firmographics

Firmographics
Name
Redesign Science
Legal name
Redesign Science
Website
https://redesignscience.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Redesign Science is a pre-revenue, New York-based computational biotechnology company that combines physics-based molecular dynamics with generative AI through its NUVO™ platform to discover first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™) for oncology, autoimmune, and rare disease indications.
Ownership category
akta.pro rank

Redesign Science industry classification

Industry
Product category
Computational Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational drug discovery
  • Molecular dynamics simulation
  • Generative AI drug design
  • Small molecule therapeutics
  • Protein interaction modulators

Where Redesign Science is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Redesign Science business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Therapeutic Pipeline Development: Pre-revenue biotech company developing small molecule therapeutics. Revenue will be generated through partnering deals with pharmaceutical companies, licensing agreements, or eventual product sales upon regulatory approval.

Distribution channels1 record

Marketing channels2 records

Redesign Science product offering

Product offering

Core offering

Redesign Science develops the NUVO™ platform, which combines physics-based atomic-level molecular dynamics with generative AI to identify druggable binding sites on proteins and design novel small molecules. The platform powers the company's internal pipeline of first-in-class Targeted Protein Interaction Modulators (TPIM™) across oncology, autoimmune, and rare disease indications, intended to be monetized through pharmaceutical licensing and partnership deals.

Product overview

Redesign Science operates as a unified platform-plus-products architecture centered on its NUVO™ technology platform, which integrates physics simulation with generative AI. The NUVO platform consists of three core sub-products: NUVO Matisse (enhanced sampling physics for structural data), NUVO Picasso (generative AI for novel compounds), and NUVO Cézanne (machine learning for predictive scoring). This platform serves the company's internal therapeutics pipeline of first-in-class small molecule TPIM™ (Targeted Protein Interaction Modulators) across oncology, autoimmune, and rare disease indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • NUVO™ Platform Integrated physics, chemistry, and synthetic data platform that combines physics simulation with generative AI to enable dynamic structure-based drug discovery and serves the company's internal small molecule therapeutics pipeline.
  • TPIM™ (Targeted Protein Interaction Modulators) First-in-class small molecule therapeutic modality developed by Redesign Science to modulate targeted protein-protein interactions and provide unprecedented control over cellular biology, pursued across oncology, autoimmune, and rare disease indications.

Companies that use Redesign Science

Customer profile

Segments1 record

Ideal customer profiles1 record

Redesign Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Redesign Science partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Redesign Science competitors and assessment

Company assessment

Direct peers

  • Insitro: Machine learning-driven drug discovery company combining high-throughput biology with predictive models for small molecule therapeutics. Comparable platform-plus-pipeline business model with pharma collaborations.
  • Atomwise: AI-focused small molecule drug discovery company using structure-based deep learning to screen billions of compounds. Comparable as a tech-first platform pursuing pharma partnerships and internal programs.
  • Schrödinger, Inc. Public computational drug discovery company combining physics-based molecular simulation with ML for small molecule discovery. Most directly comparable to Redesign Science given the shared physics-first platform philosophy and pharma-licensing business model.
  • Relay Therapeutics: Clinical-stage precision medicine company using protein motion visualization and computational chemistry to discover small molecule drugs. Closely aligned with Redesign Science's NUVO Matisse approach to leveraging dynamic protein structures for drug discovery.
  • XtalPi: AI and physics-based drug discovery company combining quantum physics, molecular dynamics, and AI for small molecule and crystal design. Directly comparable technology stack and CRO/partnership model.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning for small molecule therapeutics. Comparable as a publicly-listed AI/biotech platform advancing an internal pipeline plus pharma partnerships.

Broad incumbents

  • Isomorphic Labs: Alphabet-backed AI drug discovery company leveraging DeepMind's protein structure prediction (AlphaFold) for drug discovery. Broad incumbent with significantly more capital and the ability to leverage Alphabet's AI infrastructure.

Emerging players

  • Iambic: AI-driven drug discovery company combining physics-based modeling with generative AI for small molecule design. Emerging player with significant overlap to Redesign Science's integrated physics+AI platform approach.
  • Generate Biomedicines: Generative biology company using machine learning to design novel protein therapeutics. Partially overlapping as a tech-first platform company using AI for therapeutic design, though focused on biologics rather than small molecules.
  • Celeris Therapeutics: AI-driven degrader and small molecule discovery company using graph neural networks and physics-based approaches. Comparable as an emerging computational platform pursuing difficult-to-drug targets through AI/ML approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Redesign Science social profiles

Digital presence

Redesign Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Redesign Science leadership team

Management profile

Number of profiles

Profiles1 record

Redesign Science funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Redesign Science M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redesign Science

What does Redesign Science do?

Redesign Science develops the NUVO™ platform, which combines physics-based atomic-level molecular dynamics with generative AI to identify druggable binding sites on proteins and design novel small molecules. The platform powers the company's internal pipeline of first-in-class Targeted Protein Interaction Modulators (TPIM™) across oncology, autoimmune, and rare disease indications, intended to be monetized through pharmaceutical licensing and partnership deals.

Is Redesign Science a public or private company?

Redesign Science is a private company. It is classified as venture growth investor backed and is currently operating.

When was Redesign Science founded?

Redesign Science was founded in 2017. It employs 1 to 10 people.

Where is Redesign Science based?

Redesign Science is headquartered in New York, United States, in the North America region.

How does Redesign Science make money?

One revenue line is on record: therapeutic Pipeline Development.

Who are Redesign Science's main competitors?

Direct peers on record are Insitro, Atomwise, Schrödinger, Inc., Relay Therapeutics, XtalPi and Recursion Pharmaceuticals. Isomorphic Labs is listed as a broad incumbent. Emerging players are Iambic, Generate Biomedicines and Celeris Therapeutics.

Does Redesign Science have an API?

No public API is recorded for Redesign Science.

What industry is Redesign Science in?

Redesign Science's product category is Computational Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AiThorityRedesign Science Raises $15 Million to Advance Computational Structure-Based Drug DiscoveryRedesign Science completed Seed-2 and Seed-3 financings for $15 million to advance computational structure-based drug discovery. The company uses physics-based simulations to identify drug sites in dynamic proteins, targeting cancer and inflammatory bowel disease. Proceeds will expand cloud infrastructure and co-development partnerships.PR NewswireRedesign Science Raises $15M to Advance Computational Structure-Based Drug DiscoveryRedesign Science, a computational drug discovery biotech, announced on Dec. 8, 2021 that it completed Seed-2 and Seed-3 rounds totaling $15 million. The $5 million Seed-2 was led by Collaborative Fund and the $10 million Seed-3 by Kaitai Capital. Proceeds will fund cloud computing infrastructure, screening algorithms and an internal pipeline.FinSMEsRedesign Science Raises $15M in Seed-2 and Seed-3 FundingRedesign Science, a New York-based computational drug discovery firm, has raised $15 million in Seed-2 and Seed-3 funding. The investment round was led by Collaborative Fund and 5Y Capital, with participation from several other venture capital firms including Notation Capital and Third Kind Venture Capital. The company plans to utilize these funds to expand its cloud computing infrastructure and scale its core screening algorithms across various biological target classes.Venture Capital Access OnlineRedesign Science Raises $15M to Advance Computational Structure-Based Drug DiscoveryRedesign Science announced the completion of Seed-2 and Seed-3 financings totaling $15 million to advance its computational structure-based drug discovery platform. The company plans to use the proceeds to expand cloud computing infrastructure, refine screening algorithms, and launch an internal pipeline of early-stage asset development alongside strategic co-development partnerships.CoreweaveRedesign Science: Accelerating Molecular Dynamic SimulationRedesign Science partnered with CoreWeave to scale its molecular dynamic simulation platform, accessing tens of thousands of GPUs on-demand to accelerate early-stage drug discovery. This collaboration enabled the company to reduce its cloud spending by 84% while increasing simulation speed and timescale accuracy.PR NewswireRedesign Science and OpenEye Scientific announce strategic partnershipRedesign Science and OpenEye Scientific have entered into a strategic partnership to integrate OpenEye's cloud-based Orion computational platform into Redesign's molecular dynamics drug discovery platform. OpenEye took an equity stake in Redesign during its recently-closed seed investment round, with the partnership designed to allow Redesign to scale its drug discovery workflows without proportional increases in human costs or development times. Redesign is currently advancing drug discovery programs with multiple biotech partners through this technology integration.